This bill, the Healthy Mothers, Healthy Babies Act of 2026, directs a U.S. foreign assistance agency to expand access to multiple micronutrient supplements (MMS) — including prenatal vitamins — and other proven maternal and child health interventions in selected partner countries. It requires the agency to choose priority countries using set criteria, publish a 5-year maternal and child health strategy, and provide annual reports to Congress for five years describing progress, funding, and lessons learned. The bill authorizes up to $150,000,000 per year for fiscal years 2026 through 2030 from the Department of State Global Health Programs Account to carry out the MMS scale-up section. The bill also defines the term "relevant foreign assistance agency" as the agency primarily responsible for implementing U.S. foreign assistance under the Foreign Assistance Act of 1961.
If enacted, the United States would focus more foreign aid on expanding prenatal vitamins and other high-impact maternal and child health services in selected countries. The law would require public strategy documents and yearly reports to Congress about which countries get support, how many women are reached, and how funds are used. The bill’s findings state that MMS are American-made and that this activity could support American factory jobs and U.S. diplomatic and economic interests, but the bill does not itself change domestic healthcare services.
The bill authorizes up to $150,000,000 to be appropriated each year for fiscal years 2026 through 2030 from the State Department Global Health Programs Account for scaling up MMS coverage. The bill’s findings note a $4 per pregnancy cost for MMS and reference a $250,000,000 philanthropic commitment, but the bill does not provide a full government cost estimate or a Congressional Budget Office score. No publicly available information on total federal cost beyond the stated authorization is included in the bill text.
The bill’s findings and provisions state that expanding MMS and other low-cost interventions can prevent maternal and child deaths, improve birth outcomes, and reduce anemia. It frames immunization and other interventions as highly cost-effective, and says U.S. leadership on maternal and child health advances U.S. foreign policy, national security, and economic interests. The bill cites trial evidence and past investments that supporters say show MMS are superior to iron-folic acid tablets and that scaling up MMS could save lives and improve newborn outcomes.
No publicly available information on opposition views or arguments appears in the bill text or the provided metadata.